Orphan Drug Exclusivity, Collaborations, and New Drug Submissions Boost Growth - Research Report on Raptor Pharmaceutical,

Orphan Drug Exclusivity, Collaborations, and New Drug Submissions Boost Growth
     - Research Report on Raptor Pharmaceutical, Seattle Genetics, Arena
              Pharmaceuticals, WellCare, and Impax Laboratories

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, July 1, 2013

NEW YORK, July 1, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Raptor
Pharmaceutical Corp. (NASDAQ: RPTP), Seattle Genetics, Inc. (NASDAQ: SGEN),
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), WellCare Health Plans, Inc. (NYSE:
WCG), and Impax Laboratories Inc. (NASDAQ: IPXL). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Raptor Pharmaceutical Corp. Research Report

On June 25, 2013, Raptor Pharmaceutical Corp. (Raptor Pharmaceutical)
announced that the Office of Orphan Product Development at the Food and Drug
Administration (FDA) has granted the Company orphan drug exclusivity for
PROCYSBI (cysteamine bitartrate) delayed-release capsules for the management
of nephropathic cystinosis patients of the age six and above. According to the
Company, nephropathic cystinosis comprises 95% of cases of cystinosis, a rare,
life-threatening metabolic lysosomal storage disorder that causes toxic
accumulation of cysteine in all cells, tissues, and organs in the body. If
untreated, the disease is usually fatal by the end of the first decade of
life. Thomas E. Daley, Chief Business Officer of Raptor Pharmaceutical, said,
"The exclusivity also adds incremental protection alongside our issued patents
listed in the FDA's Orange Book with expirations in 2027." The exclusivity
period began on the date of FDA approval (April 30, 2013), and will last seven
years, subject to certain exceptions. The Full Research Report on Raptor
Pharmaceutical Corp. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/a301_RPTP]

--

Seattle Genetics,Inc. Research Report

On June 25, 2013, Seattle Genetics, Inc. (Seattle Genetics) announced that it
has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer
HealthCare (Bayer). With this relationship, Bayer will pay upfront and option
exercise fees of up to $20 million for worldwide rights to use Seattle
Genetics' auristatin-based ADC technology with antibodies to several oncology
targets. Additionally, Seattle Genetics stated that it is eligible to receive
up to $500 million in potential milestone payments, as well as royalties on
worldwide net sales of any resulting products under the multi-target
collaboration. Natasha Hernday, Vice President, Corporate Development, at
Seattle Genetics, said, "Across internal and collaborator programs, there are
more than 15 ADCs in clinical development using our technology, and we have
the potential to receive more than $3.5 billion in future milestones plus
royalties from these strategic alliances." The Full Research Report on Seattle
Genetics, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/f796_SGEN]

--

Arena Pharmaceuticals,Inc. Research Report

On June 26, 2013, Arena Pharmaceuticals, Inc. (Arena) announced that Eisai
Limited, a subsidiary of Eisai Inc. (Eisai), has submitted a New Drug
Submission (NDS) for BELVIQ (lorcaserin HCl) with Health Canada. According to
Arena, BELVIQ is being evaluated in Canada as an adjunct to a reduced-calorie
diet and increased physical activity for chronic weight management (including
weight loss and weight maintenance) in adult obese patients (initial body mass
index, or BMI, ≥ 30 kg/m2), or overweight patients (initial BMI ≥ 27 kg/m2) in
the presence of at least one additional cardiovascular risk factor (e.g.,
hypertension, dyslipidemia, type 2 diabetes, or sleep apnea). Arena
manufactures BELVIQ in Switzerland, and sells the finished product to Eisai
for distribution. In connection with the NDS, Arena reported that it will
receive a milestone payment of $500,000 from Eisai. The Full Research Report
on Arena Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/6991_ARNA]

--

WellCare Health Plans,Inc. Research Report

On June 26, 2013, WellCare Health Plans, Inc. (WellCare) announced that it is
supporting healthy eating habits among low-income youth and their families by
sponsoring 22 community gardens across Georgia. According to WellCare, this
statewide initiative involves planting and growing gardens in local
communities in order to provide easy access to nutritionally rich food that
may otherwise be unavailable to low-income families, while encouraging a sense
of community ownership. Jesse Thomas, WellCare's South Division President,
said, "Across Georgia, WellCare is working to engage with our communities on
healthy eating and healthy living." WellCare informed that this initiative was
launched in May 2013 and will continue throughout the summer of 2013. The Full
Research Report on WellCare Health Plans, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/be42_WCG]

--

Impax Laboratories Inc. Research Report

On June 25, 2013, Impax Laboratories Inc. (Impax) announced that Dr. Larry Hsu
plans to retire as President and CEO of the Company. Dr. Hsu will remain in
his current position with the Company until a new CEO is named, and will also
remain a member of the Company's Board of Directors following the appointment
of his successor. Bob Burr, Chairman of the Board of Directors of Impax, said,
"Since becoming CEO in 2006, Larry has led Impax through an important period
of substantial growth resulting in a four-fold increase in revenues, a strong
balance sheet, initiating the Company's brand strategy and successfully
positioning the Company for long-term future growth." He added, "The Board of
Directors remains confident in and committed to the Company's strategic
direction. We are focused on finding a successor CEO that will lead Impax
through its future growth." The Full Research Report on Impax Laboratories
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/425d_IPXL]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.